Our Commitment - LB Pharmaceuticals

Lead. Live. Boldly.

Lead. Live. Boldly.

Our Commitment

Purpose-driven and impatient for progress

Lead. Live. Boldly.

Our mission is to boldly advance high-impact therapies to help people with brain disorders live life more fully.

Beyond one’s health, brain disorders can affect a person’s ability to work, connect, communicate, and be fully present with the people they love. They can also place a profound burden on families, care partners, and communities.

We believe meaningful progress requires treatments designed to address the complexity of these conditions and the realities of living with them. AT LB, that means advancing novel therapies with the potential to rapidly and effectively address multiple dimensions of brain disorders while also being practical for healthcare providers to use and easy for patients to stay on treatment.

Woman sitting indoors during a conversation

We believe meaningful progress requires treatments designed to address the complexity of these conditions and the realities of living with them. At LB, that means advancing novel therapies with the potential to rapidly and effectively address multiple dimensions of brain disorders while also being practical for healthcare providers to use and easy for patients to stay on treatment.

Lead. Live. Boldly.

A company built for this moment

Swipe to explore the cards below

Purposeful innovation

LB-102 is an investigational new chemical entity built on the well-established heritage of amisulpride and designed to address its limitations.

Derisked, focused strategy

A validated antipsychotic mechanism, extensive clinical and real-world experience with amisulpride, and strong late-stage data support a streamlined path in schizophrenia with a single Phase 3 trial based on positive FDA feedback. Multiple development opportunities in mood and other neuropsychiatric disorders.

Large opportunity to make a difference

LB-102 has the potential to provide meaningful development opportunities across a wide variety of brain disorders and multiple symptom domains due to its mechanism that is unique from approved medicines in the U.S. for brain disorders.

Experienced operators

Led by seasoned drug developers and commercially successful industry leaders with experience building strong teams and advancing great science.

“We are building a fully-integrated neuromedicines company with the capabilities, focus, and determination to become an important force in the treatment of brain disorders — starting with LB-102 and extending to the patients and families in need of better options.”

Heather Turner
Chief Executive Officer

Life at LB

Join our growing team

The work ahead will take more than good science. It will take a team that is energized by complexity, motivated by patient impact, and ready to help shape the trajectory of our company at this defining stage. Learn more about the people, values, and opportunities at LB.

Explore work at LB

Lead. Live. Boldly.